Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Gala Health vs PreventiveMD

Gala Health
Graded #17

Higher grade

vs+6.5
PreventiveMD
Graded #53

Lower grade

The verdict

Gala Health takes it — 82.9/100 to 76.4/100.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePreventiveMD +1
84
85
Dose & formulationGala Health +1
83
82
Clinical oversightGala Health +3
85
82
Labs & monitoringGala Health +30
83
53
FulfillmentGala Health +5
88
83
Contract termsGala Health +11
66
55
Gala Health · left barPreventiveMD · right bar

The numbers

MetricGala HealthPreventiveMD
WeighScore82.9/10076.4/100
GradeB−C
Scorecard rank#17#53
SemaglutideNot disclosed$83/mo (as low as, term not published, all-in, compounded)
Tirzepatide$179/mo (yearly subscription)$97/mo (as low as, term not published, all-in, compounded)
CoverageAll 50 states36 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Gala Health

Graded #17 · B−

Strengths

  • Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
  • Prices are published openly rather than quiz-gated, with all doses included at the one rate
  • All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet — injection only
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
PreventiveMD

Graded #53 · C

Strengths

  • Compounded semaglutide from $83/mo and tirzepatide from $97/mo, billed as one all-in monthly price
  • Brand Wegovy, Zepbound, and Foundayo (oral GLP-1) available on the same platform
  • US-licensed provider reviews requests within 24 hours — no video visit required
  • You aren't charged until a provider approves; checkout places an authorization hold only
  • LegitScript-certified; works exclusively with state-licensed US 503A compounding pharmacies

Where it loses points

  • Both figures are 'as low as' rates and the qualifying term is not published anywhere — the checkout is gated, so whether $97 is month-to-month or a multi-month prepay cannot be established before signing up
  • Brand-name routes are priced separately and do carry a fee: $49/mo membership plus medication from $149/mo for Foundayo and Wegovy, from $299/mo for Zepbound
  • No state count is published, and a state-variant waitlist implies some states are unserved
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard